P453: The significance of the concentration of antibodies to infliximab on the frequency of loss of response when alternating the original drug infliximab and its biosimilar in patients with ulcerative colitis.ECCO’23 CopenhagenYear: 2023
Authors: Zviaglova, M.(1)*;Knyazev, O.(1);Kagramanova, A.(1);Lischinskaya, A.(1);Podolskaya, D.(2);Nanaeva, B.(2);
(1)Moscow Clinical Scientific Center named after A. S. Loginov, Department of IBD, Moscow, Russian Federation;(2)National Medical Research Сenter of Coloproctology named after A. N. Ryzhykh, Department of IBD, Moscow, Russian Federation;
P454: No increased postoperative risk of venous thromboembolism nor infectious complications after JAK inhibitor exposure in patients with ulcerative colitis undergoing colectomyECCO’23 CopenhagenYear: 2023
Authors: De Greef, I.(1)*;Bislenghi, G.(2);Terrasson, I.(2);Sabino, J.(1);Ferrante, M.(1);D'Hoore, A.(2);Vermeire, S.(1);Verstockt, B.(1);
(1)KU Leuven, Department of Chronic Diseases- Metabolism and Ageing CHROMETA, Leuven, Belgium;(2)University hospitals Leuven, Department of Abdominal Surgery, Leuven, Belgium;
P455: Comparison of two strategies for the management of post-operative recurrence in Crohn's disease patients with one clinical risk factor: a multicentre IG-IBD studyECCO’23 CopenhagenYear: 2023
Authors: Dragoni, G.(1)*;Castiglione, F.(2);Bezzio, C.(3);Pugliese, D.(4);Spagnuolo, R.(5);Viola, A.(6);Cocomazzi, F.(7);Aratari, A.(8);Savarino, E.V.(9);Balestrieri, P.(10);Onali, S.(11);Viganò, C.(12);Ribaldone, D.G.(13);Innocenti, T.(14);Testa, A.(2);Saibeni, S.(3);Privitera, G.(4);Milla, M.(14);Armuzzi, A.(15);Fantini, M.C.(11);Fiorino, G.(16);
(1)Careggi University Hospital, Department of Gastroenterology, Firenze, Italy;(2)AOU Federico II Napoli, Gastroenterology- Department of Clinical Medicine and Surgery, Naples, Italy;(3)ASST Rhodense, IBD Center- Gastroenterology Unit- Rho Hospital, Rho- Milan, Italy;(4)Fondazione Policlinico Universitario "A. Gemelli" IRCCS, CEMAD - IBD UNIT- Dipartimento di Scienze Mediche e Chirurgiche, Rome, Italy;(5)Magna Graecia University, Department of Health Science, Catanzaro, Italy;(6)University of Messina, IBD-Unit- Department. of Clinical and Experimental Medicine, Messina, Italy;(7)Fondazione "Casa Sollievo della Sofferenza"- IRCCS, Department of Gastroenterology and Endoscopy, San Giovanni Rotondo, Italy;(8)San Filippo Neri Hospital, IBD Unit, Rome, Italy;(9)Azienda Ospedaliera-University of Padua, Inflammatory Bowel Disease Unit, Padua, Italy;(10)Campus Bio-Medico University, Gastroenterology Unit, Rome, Italy;(11)University of Cagliari, Department of Medical Science and Public Health- Gastroenterology Unit, Cagliari, Italy;(12)University of Milano-Bicocca, Gastroenterology Division ASST Monza Ospedale San Gerardo - Department of Medicine and Surgery, Monza, Italy;(13)University of Turin, Department of Medical Sciences, Turin, Italy;(14)Careggi University Hospital, Department of Gastroenterology, Florence, Italy;(15)IRCCS Humanitas Research Hospital, IBD Center, Rozzano- Milan, Italy;(16)IRCCS Ospedale San Raffaele, Gastroenterology and Endoscopy, Milan, Italy;
P456: Magnetic resonance enterography findings at week 46 after biological treatment predict long-term clinical outcomes in Crohn's disease patientsECCO’23 CopenhagenYear: 2023
Authors: Fernandez Clotet, A.(1)*;Ordás, I.(2);Masamunt, M.C.(3);Caballol, B.(3);Rodriguez, S.(4);Panés, J.(3);Ricart, E.(5);Rimola, J.(4);
(1)IBD Unit. Hospital Clinic de Barcelona, Gastroenterology, Barcelona, Spain;(2)IBD Unit. Hospital Clinic de Barcelona, Gastroenteroloy, Barcelona, Spain;(3)IBD Unit- Hospital Clinic de Barcelona, Gastroenterology, Barcelona, Spain;(4)IBD Unit- Hospital Clinic de Barcelona, Radiology, Barcelona, Spain;(5)IBD Unit- Hospital Clinic de Barcelona, Gasteroenterology, Barcelona, Spain;
P457: Treatment duration of ustekinumab in patients with Crohn's disease (CD) and psoriasis (PSO) – real-world evidence from German claims dataECCO’23 CopenhagenYear: 2023
Authors: Kosa, F.(1);Nair, S.(1);He, J.(1);Lin, X.(1);Di Scala, L.(1);Lehne, M.(2)*;Ghiani, M.(3);Maywald, U.(4);Wilke, T.(3);
(1)Janssen, Global Services LLC, Raritan NJ, United States;(2)Cytel, Real World Advanced Analytics, Berlin, Germany;(3)IPAM - Institut für Pharmakoökonomie und Arzneimittellogistik e.V., n/a, Wismar, Germany;(4)AOK Plus, Unternehmensbereich Versorgung, Dresden, Germany;
P458: Low adherence to Mediterranean diet is associated with increased adipose tissue in patients with ulcerative colitis (UC) after pouch surgery: a cross sectional studyECCO’23 CopenhagenYear: 2023
Authors: Pfeffer-Gik, T.(1)*;Godny, L.(1);Ollech, J.(1);Wasserberg, N.(2);White, I.(2);Cohen, S.(1);Broitman, Y.(1);Avni-Biron, I.(1);Banai, H.(1);Snir, Y.(1);Yanai, H.(1);Yackobovich Gavan, M.(3,4);Shimon, I.(5);Tsvetov, G.(5);Barkan, R.(1);Dotan, I.(1);
(1)Rabin Medical center- affiliated to the Sackler Faculty of Medicine- Tel Aviv University, Division of Gastroenterology, Petah Tikva, Israel;(2)Rabin Medical center- affiliated to the Sackler Faculty of Medicine- Tel Aviv University, Colorectal Unit- Division of Surgery, Petah Tikva, Israel;(3)Schneider Childrens Medical Center of Israel, The Jesse Z and Sara Lea Shafer Institute for Endocrinology and Diabetes- National Center for Childhood Diabetes, Petah Tikva, Israel;(4)Tel Aviv University, Dept. of Epidemiology and Preventive Medicine- School of Public Health- Sackler Faculty of Medicine, Tel Aviv, Israel;(5)Rabin medical center- Beilinson campus- affiliated to the Sackler Faculty of Medicine- Tel Aviv University, Institute of endocrinology- diabetes and metabolism, Petah Tikva, Israel;
P459: Hospitalization, use of biologics and surgery rates in inflammatory bowel diseases: a single-center comparative analysis between public and private healthcare systems in a tertiary unit from Latin AmericaECCO’23 CopenhagenYear: 2023
Authors: Zacharias, P.(1);Perussolo, M.(2);Magro, D.O.(3);Barauna, F.D.S.B.(2);KotzeMD- PhD, P.G.(4)*;
(1)Pontificia Unmiversidade Católica do Paraná PUCPR, Colorectal Surgery Unit, Curitiba, Brazil;(2)Pontificia Universidade Católica do Paraná PUCPR, Colorectal Surgery Unit, Curitiba, Brazil;(3)Universidade Estadual de Campinas UNICAMP, Colorectal Surgery Unit, Campinas, Brazil;(4)Pontificia Universidade Católica do Paraná PUCPR, IBD outpatient Clinics, Curitiba, Brazil;
P460: Preoperative nutrition supplementation may prevent one-year endoscopic recurrence in Crohn's disease patientsECCO’23 CopenhagenYear: 2023
Authors: Inniss, S.(1,2)*;Simpson, K.(1);Fragkos, K.(1);Wood, C.(1);Smith, A.(2);Rahman, F.(1,2);
(1)University College London Hospitals NHS Foundation Trust, Gastrointestinal Services, London, United Kingdom;(2)University College London, Eastman Dental Institute, London, United Kingdom;
P461: Rapid response to appendectomy in the majority of patients with refractory Ulcerative ColitisECCO’23 CopenhagenYear: 2023
Authors: Adamou, A.(1)*;Bercher, M.(1);Iesalnieks, I.(1);Streetz, K.(2);
(1)Evangelisches Krankenhaus Kalk Cologne, Surgery, Cologne, Germany;(2)Evangelisches Krankenhaus Kalk Cologne, Gastroenterology, Cologne, Germany;Department of Surgery
P462: Delayed Responders with Ustekinumab in Ulcerative Colitis Have Increased Inflammatory Burden but Similar Long-term Outcomes as Early RespondersECCO’23 CopenhagenYear: 2023
Authors: Wong, E.(1);Dulai, P.(2);Marshall, J.(1);Jairath, V.(3);Reinisch, W.(4);Narula, N.(1)*;
(1)McMaster University, Department of Medicine Division of Gastroenterology and Farncombe Family Digestive Health Research Institute, Hamilton, Canada;(2)Northwestern University, Division of Gastroenterology, Chicago, United States;(3)Western University, Department of Medicine Division of Gastroenterology, London, Canada;(4)Medical University of Vienna, Department of Internal Medicine III Division of Gastroenterology and Hepatology, Vienna, Austria;
P463: Crohn's disease–associated anorectal cancer has a poor prognosis with high local recurrence: a subanalysis of the Nationwide Japanese StudyECCO’23 CopenhagenYear: 2023
Authors: Ogino, T.(1,2)*;Mizushima, T.(2);Sekido, Y.(1);Fujii, M.(3);Eguchi, H.(1);Nezu, R.(4);Ikeuchi, H.(5);Uchino, M.(5);Futami, K.(6);Okamoto, K.(7);Ajioka, Y.(8);Sugihara, K.(9);Ishihara, S.(10);
(1)Osaka University, Department of Gastroenterological Surgery, Osaka, Japan;(2)Osaka University, Department of Therapeutics for Inflammatory Bowel Diseases, Osaka, Japan;(3)Osaka University, Division of Health Sciences, Osaka, Japan;(4)Osaka Central Hospital, Department of Surgery, Osaka, Japan;(5)Hyogo College of Medicine, Department of Inflammatory Bowel Disease Surgery, Nishinomiya, Japan;(6)Fukuoka University Chikushi Hospital, Department of Surgery, Chikushino, Japan;(7)Tokyo Yamate Medical Center, Department of Coloproctology, Tokyo, Japan;(8)Niigata University, Department of Pathology, Niigata, Japan;(9)Tokyo Medical and Dental University, Department of Gastrointestinal Surgery, Tokyo, Japan;(10)The University of Tokyo, Department of Surgical Oncology, Tokyo, Japan;The Study Group for Inflammatory Bowel Disease Associated Intestinal Cancers by the Japanese Society for Cancer of the Colon and Rectum
P464: Effects of ozanimod on histologic remission and mucosal healing over 3 years of continuous treatment in patients with ulcerative colitisECCO’23 CopenhagenYear: 2023
Authors: Panaccione, R.(1)*;Danese, S.(2);Wolf, D.C.(3);Canavan, J.B.(4);Jain, A.(4);Wu, H.(4);Petersen, A.(4);Afzali, A.(5);Abreu, M.T.(6);
(1)Inflammatory Bowel Disease Clinic, Medicine, Calgary, Canada;(2)IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Gastroenterology and Endoscopy, Milan, Italy;(3)Atlanta Gastroenterology Associates LLC, Medicine, Atlanta, United States;(4)Bristol Myers Squibb, Clinical Research, Princeton, United States;(5)University of Cincinnati- Cincinnati, Division of Digestive Diseases, Cincinnati, United States;(6)The University of Miami Miller School of Medicine, Medicine, Miami, United States;
P465: Health-related quality of life from the Inflammatory Bowel Disease Questionnaire in patients with ulcerative colitis treated with etrasimod in the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trialsECCO’23 CopenhagenYear: 2023
Authors: Armuzzi, A.(1)*;Rubin, D.T.(2);Schreiber, S.(3);Panés, J.(4);Fellmann, M.(5);Bartolome, L.(6);Goetsch, M.(7);Bhattacharjee, A.(8);Wu, J.(9);Chaparro, M.(10);Dubinsky, M.C.(11);
(1)IRCCS Humanitas Research Hospital- Rozzano, IBD Center, Milan, Italy;(2)University of Chicago Medicine Inflammatory Bowel Disease Center, Section of Gastroenterology- Hepatology and Nutrition, Chicago- Illinois, United States;(3)Kiel University, University Hospital Schleswig-Holstein- Department Internal Medicine I, Kiel, Germany;(4)Hospital Clínic de Barcelona- IDIBAPS- CIBERehd, Gastroenterology, Barcelona, Spain;(5)Pfizer AG, Global Medical Affairs, Zurich, Switzerland;(6)Pfizer Inc, Global Health Economics & Outcomes Research- Inflammation & Immunology, New York- New York, United States;(7)Pfizer AG, Global Clinical Development, Zurich, Switzerland;(8)Pfizer Healthcare India Pvt. Ltd, Biostatistics, Chennai, India;(9)Pfizer Inc, Biostatistics, Groton- Connecticut, United States;(10)Hospital Universitario de La Princesa- Instituto de Investigación Sanitaria Princesa IIS-Princesa- Universidad Autónoma de Madrid UAM- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD-, Gastroenterology, Madrid, Spain;(11)Icahn School of Medicine- Mount Sinai, Feinstein IBD Center, New York- New York, United States;
P466: Efficacy and safety outcomes in patients with moderate to severe ulcerative colitis stratified by ethnicity and race: a pooled analysis of data from GEMINI 1, VARSITY, and VISIBLE 1ECCO’23 CopenhagenYear: 2023
Authors: Mukherjee , R.(1);Khan , R.M.Q.(1);Liu , J.J.(2);Ananthakrishnan , A.N.(3);Lichtenstein , G.R.(4)*;Uddin , S.(1);Young , L.(1);Boules , M.(1);Adamson , P.(2);Reeves , V.(5);
(1)Takeda Pharmaceuticals U.S.A.- Inc., Medical, Lexington, United States;(2)Morehouse School of Medicine, Division of Gastroenterology, Atlanta, United States;(3)Massachusetts General Hospital and Harvard Medical School, Division of Gastroenterology, Boston, United States;(4)University of Pennsylvania, School of Medicine, Philadelphia, United States;(5)GI Associates and Endoscopy Center, GI Alliance, Jackson, United States;
P467: 5-ASA is not superior to no-maintenance in patients with newly diagnosed Crohn's disease - a nationwide cohort from the epi-IIRNECCO’23 CopenhagenYear: 2023
Authors: Atia, O.(1);Goren, I.(2)*;Sharar Fischler, T.(2);Loewenberg Weisband, Y.(3);Greenfeld, S.(4);Kariv, R.(5);Ledderman, N.(6);Matz, E.(7);Magen Rimon, R.(8);Dotan, I.(2);Turner, D.(1);Yanai, H.(2);
(1)Shaare Zedek Medical Center, Juliet Keidan Institute of Pediatric Gastroenterology Hepatology and Nutrition, Jerusalem, Israel;(2)Rabin Medical Center, Division of Gastroenterology, Petah Tikva, Israel;(3)Clalit Health Services, Clalit Research Institute, Tel Aviv, Israel;(4)Maccabi health services, Maccabi health services, Tel Aviv, Israel;(5)Maccabi Healthcare Services, Gastroenterology, Tel Aviv, Israel;(6)Meuhedet Health Services, Meuhedet Health Services, Tel Aviv, Israel;(7)Leumit Health Services, Leumit Health Services, Tel Aviv, Israel;(8)Rambam Medical Center, Pediatric Gastroenterology & Nutrition institute, Haifa, Israel;
P468: Association of uncontrolled disease with quality of life and healthcare resource utilisation in Ulcerative Colitis patients treated with advanced therapy in the United StatesECCO’23 CopenhagenYear: 2023
Authors: Igho-Osagie, E.(1);Knight, H.(2);Barlow, S.(3);Harvey, N.(2);Khandker, R.(1)*;
(1)Merck & Co. Inc, Center for Observational and Real World Evidence, North Wales- PA, United States;(2)Adelphi Real World, Autoimmune franchise, Bollington, United Kingdom;(3)Adelphi Real World, Statistics and Data Analytics, Bollington, United Kingdom;
P469: Effect of mirikizumab on clinical and endoscopic outcomes based on prior advanced therapy failure in patients with moderately to severely active ulcerative colitisECCO’23 CopenhagenYear: 2023
Authors: Navabi, S.(1)*;D'Haens, G.(2);Samaan, K.H.(3);Li, X.(3);Arora, V.(3);Redondo, I.(3);Danese, S.(4);
(1)Rutgers New Jersey Medical School, Gastroenterology- Hepatolgy and Obesity Medicine, Newark- NJ, United States;(2)Amsterdam University Medical Centers, Gastroenterology, Amsterdam, The Netherlands;(3)Eli Lilly and Company, Immunology, Indianapolis, United States;(4)IRCCS San Raffaele Scientific Institute, Gastroenterology and Gastrointestinal Endoscopy Unit, Milano, Italy;
P470: Evolution of asymptomatic unresected lesions in patients operated for multifocal Crohn's disease.ECCO’23 CopenhagenYear: 2023
Authors: Abdalla, S.(1)*;Lelievre, O.(2);Carbonnel, F.(3);Penna, C.(4);Benoist, S.(5);Brouquet, A.(5);
(1)Le Kremlin-Bicetre University Hospital, Department of Digestive Surgery, Le Kremlin-Bicetre, France;(2)Le Kremlin Bicetre University Hospital, Department of Digestive Surgery, Le Kremlin-Bicetre, France;(3)Le Kremlin-Bicetre University Hospital, Department of Gastroenterology, Le Kremlin-Bicetre, France;(4)Le Kremlin-Bicêtre University Hospital, Department of Digestive Surgery, Le Kremlin-Bicêtre, France;(5)Le Kremlin Bicetre University Hospital, Department of Digestive Surgery, Le Kremlin Bicetre, France;
P471: A Transcriptome-dependent Prognostic Model of Response in Patients with Ulcerative ColitisECCO’23 CopenhagenYear: 2023
Authors: Johnson, T.(1);Reinisch, W.(2);Steere, B.(3);Milch, C.(4);Harris, C.(3);Morris, N.(3);D'Haens, G.(5);Huang, K.(1);Krishnan, V.(3)*;
(1)Indiana University, Clinical and Translational Sciences Institute, Indianapolis, United States;(2)Medical University of Vienna, Clinical Department for Gastroenterology and Hepatology, Vienna, Austria;(3)Eli Lilly and Company, Immunology, Indianapolis, United States;(4)Eli Lilly and Company, Former affiliation, Indianapolis, United States;(5)Amsterdam University Medical Centers, Department of Gastroenterology, Amsterdam, The Netherlands;
P472: Cyclosporine versus infliximab in patients with Acute Severe Ulcerative Colitis: A single-centre retrospective studyECCO’23 CopenhagenYear: 2023
Authors: Karpavičiūtė, V.(1)*;Kiudelis, G.(2);Kupčinskas, J.(2);Kupčinskas, L.(2);
(1)Hospital of Lithuanian University of Health Sciences Kaunas Clinics, Department of Gastroenterology, Kaunas, Lithuania;(2)Hospital of Lithuanian University of Health Sciences Kaunas Clinics, Department of Gastroenterology- Medical Academy, Kaunas, Lithuania;
